Title:
NUCLEIC ACID DRUG AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/157730
Kind Code:
A1
Abstract:
[Problem] To provide a nucleic acid drug for treating or preventing illness or symptoms associated with expression of the p53 gene. [Solution] The present inventors have identified antisense oligonucleotides (ASOs) which act on a p53 gene transcription product. By using these relatively short oligonucleotides, the amount of p53 mRNA can be reduced and the expression of the protein can be suppressed. These ASOs can be useful in the treatment or prevention of acute kidney failure, alopecia, etc.
More Like This:
Inventors:
NAKAMURA SHINGO (JP)
MORISHITA ELLA (JP)
TAKATA RYOHEI (JP)
MORISHITA ELLA (JP)
TAKATA RYOHEI (JP)
Application Number:
PCT/JP2021/004450
Publication Date:
August 12, 2021
Filing Date:
February 05, 2021
Export Citation:
Assignee:
VERITAS IN SILICO INC (JP)
International Classes:
A61K31/7088; A61K31/7115; A61K31/712; A61K31/7125; A61K48/00; A61P1/16; A61P9/00; A61P9/04; A61P9/10; A61P13/12; A61P17/02; A61P17/14; A61P25/00; A61P25/16; A61P25/28; A61P27/16; A61P29/00; A61P35/00; A61P37/06; A61P43/00; C12N15/113
Domestic Patent References:
| WO2021002359A1 | 2021-01-07 |
Other References:
CACERES G. ET AL.: "TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients", PNAS, vol. 110, no. 40, 2013, pages 16127 - 16132, XP055783288, DOI: 10.1073/pnas.1311055110
CORTES J. ET AL.: "Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia", CANCER, vol. 118, 2012, pages 418 - 427, XP055783290, DOI: 10.1002/cncr.26292
PETTY RD. ET AL.: "Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 1994, pages 264 - 270, XP024764963
0BIKA SATOSHI ET AL.: "Design of antisense oligonucleotides", FOLIA PHARMACOLOGICA JAPONICA, vol. 148, 2016, pages 100 - 104, XP009530197, DOI: 10.1254/fpj.148.100
TAKATA R. ET AL.: "Medicinal chemistry of MRNA-targeted mid-sized molecules utilizing veritas in silico’s ibVIS-ASO platform", SAR NEWS-VERITAS IN SILICO IBVIS AS0 PLATFORM MRNA, vol. 38, 1 April 2020 (2020-04-01), pages 18 - 26
CORTES J. ET AL.: "Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia", CANCER, vol. 118, 2012, pages 418 - 427, XP055783290, DOI: 10.1002/cncr.26292
PETTY RD. ET AL.: "Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 199, no. 1, 1994, pages 264 - 270, XP024764963
0BIKA SATOSHI ET AL.: "Design of antisense oligonucleotides", FOLIA PHARMACOLOGICA JAPONICA, vol. 148, 2016, pages 100 - 104, XP009530197, DOI: 10.1254/fpj.148.100
TAKATA R. ET AL.: "Medicinal chemistry of MRNA-targeted mid-sized molecules utilizing veritas in silico’s ibVIS-ASO platform", SAR NEWS-VERITAS IN SILICO IBVIS AS0 PLATFORM MRNA, vol. 38, 1 April 2020 (2020-04-01), pages 18 - 26
Attorney, Agent or Firm:
ITO Katsuhiro et al. (JP)
Download PDF: